Pub Date : 2016-12-01DOI: 10.1080/10177833.2016.11827159
N. Altunsoy, A. Darcin, N. Dilbaz
The Restless Leg Syndrome(RLS) induced by aripiprazole is very unique albeit rare adverse effect. The patient is a 55-year-old female who presented to our outpatient clinic with the diagnosis of major depressive disorder according to DSM-IV. Patient who has been receiving venlafaxine and quetiapine with doses of 75 mg/day and 300 mg/day respectively one year, was not being followed-up regularly. The patient had complaints such as suicidal thoughts and insomnia since the onset and gained 10 kg during the treatment. She was using ramipril 5 mg/day and her blood pressure follow-ups were normal. The venlafaxine dose of the patient was elevated to 150 mg/day and dose of quetiapine was remained same at 300 mg/day. Aripiprazol with a dose of 5 mg/day was added to the treatment of the patient due to complaints on the follow-up after a month. On the next one month follow up after the aripiprazole administration, patient stated that she suffered from insomnia, restlessness on legs, urge to move her legs and she had ceased the medication after 5 days. Her complaints were recovered after the cessation of the aripiprazole administration. The biochemistry, blood glucose, hemogram, iron, ferritine, transferrin level, renal hepatic test results, thyroid function tests, B12, and folic acid levels of the patient were all within normal range. Patient was evaluated by the departments of neurology and internal medicine and no peripheral neuropathic or vascular disease were found. There were no similar complaints before the aripiprazole treatment. Treatments of venlafaxine 150 mg/day and quetiapine 300 mg/day were continued. Venlafaxine dose was elevated to 225 mg/day but this dose was terminated gradually due to onset hypertension and depressive findings, duloxetine treatment with a dose of 30 mg/day was initiated, treatment of quetiapine 300 mg/day was resumed as unchanged. Duloxetine dose was increased up to 120 mg/day. RLS symptoms were not recurred during this period. Depressive symptoms of the patient remitted and treatment have been proceeding for one year. In our case, the symptoms have been considered as a result of aripiprazole administration due to occurrence of the symptoms after the initiation of aripiprazole treatment, recovery of the symptoms after cessation of aripiprazole, absence of and organic disease causing RLS, normal lab results, and lack of similar picture in patient’s history. The patient has been using venlafaxine and quetiapine for one year and no RLS symptoms were reported since then. Although the onset venlafaxine and quetiapine medication was proceeding, RLS symptoms were not observed after cessation of aripiprazole. In literature, a case of RLS related with the combination of venlafaxine and quetiapine was reported. RLS symptoms were remitted when aripiprazole was added to treatment. The inflammation of the RLS by D2 receptor antagonists and well response of the symptoms to dopaminergic drugs such as levodopa, suggest that the dopaminerg
{"title":"Acute Urinary Retention Related with Sublingual Buprenorphine Administration","authors":"N. Altunsoy, A. Darcin, N. Dilbaz","doi":"10.1080/10177833.2016.11827159","DOIUrl":"https://doi.org/10.1080/10177833.2016.11827159","url":null,"abstract":"The Restless Leg Syndrome(RLS) induced by aripiprazole is very unique albeit rare adverse effect. The patient is a 55-year-old female who presented to our outpatient clinic with the diagnosis of major depressive disorder according to DSM-IV. Patient who has been receiving venlafaxine and quetiapine with doses of 75 mg/day and 300 mg/day respectively one year, was not being followed-up regularly. The patient had complaints such as suicidal thoughts and insomnia since the onset and gained 10 kg during the treatment. She was using ramipril 5 mg/day and her blood pressure follow-ups were normal. The venlafaxine dose of the patient was elevated to 150 mg/day and dose of quetiapine was remained same at 300 mg/day. Aripiprazol with a dose of 5 mg/day was added to the treatment of the patient due to complaints on the follow-up after a month. On the next one month follow up after the aripiprazole administration, patient stated that she suffered from insomnia, restlessness on legs, urge to move her legs and she had ceased the medication after 5 days. Her complaints were recovered after the cessation of the aripiprazole administration. The biochemistry, blood glucose, hemogram, iron, ferritine, transferrin level, renal hepatic test results, thyroid function tests, B12, and folic acid levels of the patient were all within normal range. Patient was evaluated by the departments of neurology and internal medicine and no peripheral neuropathic or vascular disease were found. There were no similar complaints before the aripiprazole treatment. Treatments of venlafaxine 150 mg/day and quetiapine 300 mg/day were continued. Venlafaxine dose was elevated to 225 mg/day but this dose was terminated gradually due to onset hypertension and depressive findings, duloxetine treatment with a dose of 30 mg/day was initiated, treatment of quetiapine 300 mg/day was resumed as unchanged. Duloxetine dose was increased up to 120 mg/day. RLS symptoms were not recurred during this period. Depressive symptoms of the patient remitted and treatment have been proceeding for one year. In our case, the symptoms have been considered as a result of aripiprazole administration due to occurrence of the symptoms after the initiation of aripiprazole treatment, recovery of the symptoms after cessation of aripiprazole, absence of and organic disease causing RLS, normal lab results, and lack of similar picture in patient’s history. The patient has been using venlafaxine and quetiapine for one year and no RLS symptoms were reported since then. Although the onset venlafaxine and quetiapine medication was proceeding, RLS symptoms were not observed after cessation of aripiprazole. In literature, a case of RLS related with the combination of venlafaxine and quetiapine was reported. RLS symptoms were remitted when aripiprazole was added to treatment. The inflammation of the RLS by D2 receptor antagonists and well response of the symptoms to dopaminergic drugs such as levodopa, suggest that the dopaminerg","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76898715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-12-01DOI: 10.5455/BCP.20151204115654
H. Ertekin, Y. H. Ertekin, B. Sahin, S. Yayla, E. Turkyilmaz, Medine Kara
ABSTRACTTurner Syndrome (TS) is the most common chromosomal anomaly in women. Its psychiatric manifestations have not been clearly defined. Occurrence of schizophrenia is higher in patients with TS than in the normal population. The literature has reported instances associating stuttering as a side effect of antipsychotic drugs, particularly clozapine-induced stuttering. We found only one case report describing aripiprazole-associated stuttering. In the present case report, we present a female patient with TS-diagnosed schizophrenia who had been treated with aripiprazole because she developed stuttering during treatment with clozapine and then developed dose-dependent stuttering with aripiprazole.
{"title":"Clozapine and aripiprazole-induced stuttering: a case report of turner syndrome with schizophrenia -","authors":"H. Ertekin, Y. H. Ertekin, B. Sahin, S. Yayla, E. Turkyilmaz, Medine Kara","doi":"10.5455/BCP.20151204115654","DOIUrl":"https://doi.org/10.5455/BCP.20151204115654","url":null,"abstract":"ABSTRACTTurner Syndrome (TS) is the most common chromosomal anomaly in women. Its psychiatric manifestations have not been clearly defined. Occurrence of schizophrenia is higher in patients with TS than in the normal population. The literature has reported instances associating stuttering as a side effect of antipsychotic drugs, particularly clozapine-induced stuttering. We found only one case report describing aripiprazole-associated stuttering. In the present case report, we present a female patient with TS-diagnosed schizophrenia who had been treated with aripiprazole because she developed stuttering during treatment with clozapine and then developed dose-dependent stuttering with aripiprazole.","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89501006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-12-01DOI: 10.5455/BCP.20160319021659
Erdal Pan, M. Ateş, A. Algul, A. Aytekin, C. Başoğlu, S. Ebrinç, M. Cetin, S. Kose
ABSTRACTObjective: Schizophrenia involves white matter abnormalities that might have a central role in the pathophysiology. Abnormal brain connectivity especially in prefrontal and temporal heteromodal cortex has been suggested as the leading structural impairment in patients with schizophrenia. In this study we examined the relationship between potential white matter changes and clinical response, as well as associations with antipsychotic treatment follow-up.Methods: 18 first-episode schizophrenia (FES) patients were recruited from the outpatient unit of the GATA (Gulhane Military Medical Academy) Haydarpasa Research and Training Hospital, between June 2009-February 2010. Fourteen patients with FES were recruited, and 16 healthy control subjects were recruited from the community. Diffusion tensor MRI (DT-MRI) was obtained from participants at baseline and after 4 weeks of standard antipsychotic treatment. A color-coded fractional anisotropy map for each 11 patient was extracted from the 4-week follow-up...
{"title":"Fractional Anisotropic Changes of Corpus Callosum Associated with Antipsychotic Treatment in First-Episode Antipsychotic Drug-Naive Patients with Schizophrenia","authors":"Erdal Pan, M. Ateş, A. Algul, A. Aytekin, C. Başoğlu, S. Ebrinç, M. Cetin, S. Kose","doi":"10.5455/BCP.20160319021659","DOIUrl":"https://doi.org/10.5455/BCP.20160319021659","url":null,"abstract":"ABSTRACTObjective: Schizophrenia involves white matter abnormalities that might have a central role in the pathophysiology. Abnormal brain connectivity especially in prefrontal and temporal heteromodal cortex has been suggested as the leading structural impairment in patients with schizophrenia. In this study we examined the relationship between potential white matter changes and clinical response, as well as associations with antipsychotic treatment follow-up.Methods: 18 first-episode schizophrenia (FES) patients were recruited from the outpatient unit of the GATA (Gulhane Military Medical Academy) Haydarpasa Research and Training Hospital, between June 2009-February 2010. Fourteen patients with FES were recruited, and 16 healthy control subjects were recruited from the community. Diffusion tensor MRI (DT-MRI) was obtained from participants at baseline and after 4 weeks of standard antipsychotic treatment. A color-coded fractional anisotropy map for each 11 patient was extracted from the 4-week follow-up...","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82222438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-12-01DOI: 10.5455/BCP.20151223092807
Özlem Önen, Handan Özek Erkuran
ABSTRACTTourette Syndrome (TS) is an inherited neuropsychiatric disorder with onset in childhood, characterized by multiple motor tics and at least one vocal tic. In many of the cases, Attention Deficit Hyperactivity Disorder (ADHD) is a frequent comorbid disorder. Many treatment options have been suggested for TS and ADHD comorbidity. In this article, we present a case diagnosed with TS and ADHD whose tics were refractory to many other suggested treatment options for Tic Disorders (TD) and worsened during the use of recommended first-line treatment agents for ADHD, that were significantly reduced by using topiramate. New therapeutic options that would be easily used and with less side effects are needed in the treatment of TD. Topiramate treatment seems like an appropriate option raising hope for the future to be used as monotherapy or in adjuvant treatment for TD. Larger trials with longer follow up are required in this field.
{"title":"Topiramate in the Adjunctıve Treatment of Tourette Syndrome: A Case Report","authors":"Özlem Önen, Handan Özek Erkuran","doi":"10.5455/BCP.20151223092807","DOIUrl":"https://doi.org/10.5455/BCP.20151223092807","url":null,"abstract":"ABSTRACTTourette Syndrome (TS) is an inherited neuropsychiatric disorder with onset in childhood, characterized by multiple motor tics and at least one vocal tic. In many of the cases, Attention Deficit Hyperactivity Disorder (ADHD) is a frequent comorbid disorder. Many treatment options have been suggested for TS and ADHD comorbidity. In this article, we present a case diagnosed with TS and ADHD whose tics were refractory to many other suggested treatment options for Tic Disorders (TD) and worsened during the use of recommended first-line treatment agents for ADHD, that were significantly reduced by using topiramate. New therapeutic options that would be easily used and with less side effects are needed in the treatment of TD. Topiramate treatment seems like an appropriate option raising hope for the future to be used as monotherapy or in adjuvant treatment for TD. Larger trials with longer follow up are required in this field.","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81473706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-12-01DOI: 10.1080/10177833.2016.11827158
N. Uvais
{"title":"Autoimmune Psychosis: Caveats in the Diagnosis","authors":"N. Uvais","doi":"10.1080/10177833.2016.11827158","DOIUrl":"https://doi.org/10.1080/10177833.2016.11827158","url":null,"abstract":"","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84897365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-12-01DOI: 10.5455/BCP.20160502090929
A. Şahpaz, S. Pehlivan, Dilhan Turkkan, Dogus Ozdemir Kara, H. Alkan
Long term use of antipsychotics, is encountered in many psychiatric disorders, especially in schizophrenia. Eosinophilic myocarditis is a rare form of myocarditis characterized by myocardial inflamation composed of mostly eosinophils. It is known that it may develop at a rate of 0.2-3 % in long term therapies, especially with clozapine use. Standart treatment can not be established because of rarity of disease and difficulties in the determination of the etiology. In this article, three cases, who have been receiving long term drug treatment for schizoaffective disorder and faced sudden death, were presented. Their autopsies were performed in our institution. When myocardial sections were examinated with light microscope, common findings with three cases were, myocyte damage accompanied with patchy distribution of perivascular and interstitial inflamatory infiltrate rich in eosinophils. When the light microscopic findings evaluated with detailed medical history, autopsy findings and toxicological analysis results, we considered these entities may have developed as a result of hypersensitivity reaction due to long term antipsychotic drug use. Eosinophilic myocarditis is encountered as a rare clinical entity and probably it is a subtype of myocarditis that is overlooked. Failure in the clinical diagnosis and delay in treatment may lead to irreversible myocardial damage and death. Endomyocardial biopsy is still the gold standard in the diagnosis of eosinophilic myocarditis. Here, we present these cases since the drug use is the most frequently accused cause, it is rarely seen in acute deaths and the diagnosis can be reached by histopathological examination.
{"title":"Eosinophilic myocarditis in long term use of antipsychotics: case series and review of the literature -","authors":"A. Şahpaz, S. Pehlivan, Dilhan Turkkan, Dogus Ozdemir Kara, H. Alkan","doi":"10.5455/BCP.20160502090929","DOIUrl":"https://doi.org/10.5455/BCP.20160502090929","url":null,"abstract":"Long term use of antipsychotics, is encountered in many psychiatric disorders, especially in schizophrenia. Eosinophilic myocarditis is a rare form of myocarditis characterized by myocardial inflamation composed of mostly eosinophils. It is known that it may develop at a rate of 0.2-3 % in long term therapies, especially with clozapine use. Standart treatment can not be established because of rarity of disease and difficulties in the determination of the etiology. In this article, three cases, who have been receiving long term drug treatment for schizoaffective disorder and faced sudden death, were presented. Their autopsies were performed in our institution. When myocardial sections were examinated with light microscope, common findings with three cases were, myocyte damage accompanied with patchy distribution of perivascular and interstitial inflamatory infiltrate rich in eosinophils. When the light microscopic findings evaluated with detailed medical history, autopsy findings and toxicological analysis results, we considered these entities may have developed as a result of hypersensitivity reaction due to long term antipsychotic drug use. Eosinophilic myocarditis is encountered as a rare clinical entity and probably it is a subtype of myocarditis that is overlooked. Failure in the clinical diagnosis and delay in treatment may lead to irreversible myocardial damage and death. Endomyocardial biopsy is still the gold standard in the diagnosis of eosinophilic myocarditis. Here, we present these cases since the drug use is the most frequently accused cause, it is rarely seen in acute deaths and the diagnosis can be reached by histopathological examination.","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88126885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-12-01DOI: 10.5455/BCP.20151203125902
M. Boysan, M. Kadak, M. Tarakçıoğlu, Zeynep Seda Sertdurak, Ö. Demirel
ABSTRACTObjective: Juvenile obsessive-compulsive disorder has been increasingly recognized in the literature. However, the developmentally sensitive screening tools for obsessive-compulsive disorder (OCD) in children and adolescents still lag behind psychometric tools developed for adult OCD. The Leyton Obsessional Inventory-Child Version is the most widely utilized screening tool for juvenile OCD assessment. Our aim was to assess psychometric properties of the Leyton Obsessional Inventory-Child Version (LOI-CV) and Obsessive Beliefs Questionnaire-Child Version (OBQ-CV).Method: The sample consisted of 805 children and adolescents, aged from 11 to 17 years. Mean age of the sample was 13.85 (SD±1.40) years. The LOI-CV, OBQ-CV, Obsessive Compulsive Inventory-Revised (OCI-R), State Trait Anxiety Inventory for Children (STAI-C) and Meta-Cognitions Questionnaire for Children (MCQ-C) were completed by respondents. The data were subjected to explanatory and confirmatory factor analyses. Internal consistency and t...
{"title":"Psychometric Properties of Turkish versions of the Leyton Obsessional Inventory-Child Version (LOI-CV) and Obsessive Beliefs Questionnaire-Child Version (OBQ-CV)","authors":"M. Boysan, M. Kadak, M. Tarakçıoğlu, Zeynep Seda Sertdurak, Ö. Demirel","doi":"10.5455/BCP.20151203125902","DOIUrl":"https://doi.org/10.5455/BCP.20151203125902","url":null,"abstract":"ABSTRACTObjective: Juvenile obsessive-compulsive disorder has been increasingly recognized in the literature. However, the developmentally sensitive screening tools for obsessive-compulsive disorder (OCD) in children and adolescents still lag behind psychometric tools developed for adult OCD. The Leyton Obsessional Inventory-Child Version is the most widely utilized screening tool for juvenile OCD assessment. Our aim was to assess psychometric properties of the Leyton Obsessional Inventory-Child Version (LOI-CV) and Obsessive Beliefs Questionnaire-Child Version (OBQ-CV).Method: The sample consisted of 805 children and adolescents, aged from 11 to 17 years. Mean age of the sample was 13.85 (SD±1.40) years. The LOI-CV, OBQ-CV, Obsessive Compulsive Inventory-Revised (OCI-R), State Trait Anxiety Inventory for Children (STAI-C) and Meta-Cognitions Questionnaire for Children (MCQ-C) were completed by respondents. The data were subjected to explanatory and confirmatory factor analyses. Internal consistency and t...","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90346306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-12-01DOI: 10.5455/BCP.20160223124107
Fatih Yavuz, S. Ulusoy, Mehtap Iskin, Fatma Betul Esen, H. Burhan, M. Karadere, N. Yavuz
ABSTRACTObjective: Acceptance and Action Questionnaire-II (AAQ-II) is a self-evaluating scale that has been developed for assessing psychological inflexibility levels. The aim of the present study is to examine reliability and validity of the Turkish version of Acceptance and Action Questionnaire-II (Turkish AAQ-II) using clinical and non-clinical sample.Methods: The study group consisted of 207 patients who have at least one diagnosis of anxiety disorders, anti-social personality disorder, unipolar depression or bipolar disorder, and 267 healthy controls. A socio-demographic form, Turkish AAQ-II, Panic Disorder Severity Scale (PDSS), Ruminative Thinking Style Questionnaire (RTSQ), Beck Depression Inventory (BDI), Padua Inventory Washington State University Revision (PI-WSUR), Short Form-36 (SF-36), STAI (State-Trait Anxiety Inventory) I-II were all administered. Internal consistency and temporal stability analyses were performed to evaluate the reliability of Turkish AAQ-II. Exploratory factor analysis a...
摘要目的:接受与行动问卷- ii (AAQ-II)是一种评估心理不灵活性水平的自评量表。本研究的目的是使用临床和非临床样本检验土耳其版接受和行动问卷- ii(土耳其AAQ-II)的信度和效度。方法:研究组包括207名至少有一种焦虑症、反社会人格障碍、单极抑郁症或双相情感障碍诊断的患者，以及267名健康对照。采用社会人口学量表、土耳其AAQ-II、恐慌障碍严重程度量表(PDSS)、反刍思维方式问卷(RTSQ)、贝克抑郁量表(BDI)、帕多瓦量表(PI-WSUR)、简表36 (SF-36)、状态-特质焦虑量表(STAI - ii)。采用内部一致性和时间稳定性分析来评估土耳其AAQ-II的可靠性。探索性因子分析
{"title":"Turkish Version of Acceptance and Action Questionnaire-II (AAQ-II): A reliability and Validity Analysis in Clinical and Non-Clinical Samples","authors":"Fatih Yavuz, S. Ulusoy, Mehtap Iskin, Fatma Betul Esen, H. Burhan, M. Karadere, N. Yavuz","doi":"10.5455/BCP.20160223124107","DOIUrl":"https://doi.org/10.5455/BCP.20160223124107","url":null,"abstract":"ABSTRACTObjective: Acceptance and Action Questionnaire-II (AAQ-II) is a self-evaluating scale that has been developed for assessing psychological inflexibility levels. The aim of the present study is to examine reliability and validity of the Turkish version of Acceptance and Action Questionnaire-II (Turkish AAQ-II) using clinical and non-clinical sample.Methods: The study group consisted of 207 patients who have at least one diagnosis of anxiety disorders, anti-social personality disorder, unipolar depression or bipolar disorder, and 267 healthy controls. A socio-demographic form, Turkish AAQ-II, Panic Disorder Severity Scale (PDSS), Ruminative Thinking Style Questionnaire (RTSQ), Beck Depression Inventory (BDI), Padua Inventory Washington State University Revision (PI-WSUR), Short Form-36 (SF-36), STAI (State-Trait Anxiety Inventory) I-II were all administered. Internal consistency and temporal stability analyses were performed to evaluate the reliability of Turkish AAQ-II. Exploratory factor analysis a...","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80404045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-12-01DOI: 10.1080/10177833.2016.11827157
E. Akçay, F. Karadag, T. Tunç
The Restless Leg Syndrome(RLS) induced by aripiprazole is very unique albeit rare adverse effect. The patient is a 55-year-old female who presented to our outpatient clinic with the diagnosis of major depressive disorder according to DSM-IV. Patient who has been receiving venlafaxine and quetiapine with doses of 75 mg/day and 300 mg/day respectively one year, was not being followed-up regularly. The patient had complaints such as suicidal thoughts and insomnia since the onset and gained 10 kg during the treatment. She was using ramipril 5 mg/day and her blood pressure follow-ups were normal. The venlafaxine dose of the patient was elevated to 150 mg/day and dose of quetiapine was remained same at 300 mg/day. Aripiprazol with a dose of 5 mg/day was added to the treatment of the patient due to complaints on the follow-up after a month. On the next one month follow up after the aripiprazole administration, patient stated that she suffered from insomnia, restlessness on legs, urge to move her legs and she had ceased the medication after 5 days. Her complaints were recovered after the cessation of the aripiprazole administration. The biochemistry, blood glucose, hemogram, iron, ferritine, transferrin level, renal hepatic test results, thyroid function tests, B12, and folic acid levels of the patient were all within normal range. Patient was evaluated by the departments of neurology and internal medicine and no peripheral neuropathic or vascular disease were found. There were no similar complaints before the aripiprazole treatment. Treatments of venlafaxine 150 mg/day and quetiapine 300 mg/day were continued. Venlafaxine dose was elevated to 225 mg/day but this dose was terminated gradually due to onset hypertension and depressive findings, duloxetine treatment with a dose of 30 mg/day was initiated, treatment of quetiapine 300 mg/day was resumed as unchanged. Duloxetine dose was increased up to 120 mg/day. RLS symptoms were not recurred during this period. Depressive symptoms of the patient remitted and treatment have been proceeding for one year. In our case, the symptoms have been considered as a result of aripiprazole administration due to occurrence of the symptoms after the initiation of aripiprazole treatment, recovery of the symptoms after cessation of aripiprazole, absence of and organic disease causing RLS, normal lab results, and lack of similar picture in patient’s history. The patient has been using venlafaxine and quetiapine for one year and no RLS symptoms were reported since then. Although the onset venlafaxine and quetiapine medication was proceeding, RLS symptoms were not observed after cessation of aripiprazole. In literature, a case of RLS related with the combination of venlafaxine and quetiapine was reported. RLS symptoms were remitted when aripiprazole was added to treatment. The inflammation of the RLS by D2 receptor antagonists and well response of the symptoms to dopaminergic drugs such as levodopa, suggest that the dopaminerg
{"title":"Psychotic Disorder or Complex Partial Seizure Disorder Due to a Sequelae of Herpes Simplex Encephalitis and Coincidental Parasagittal Meningioma","authors":"E. Akçay, F. Karadag, T. Tunç","doi":"10.1080/10177833.2016.11827157","DOIUrl":"https://doi.org/10.1080/10177833.2016.11827157","url":null,"abstract":"The Restless Leg Syndrome(RLS) induced by aripiprazole is very unique albeit rare adverse effect. The patient is a 55-year-old female who presented to our outpatient clinic with the diagnosis of major depressive disorder according to DSM-IV. Patient who has been receiving venlafaxine and quetiapine with doses of 75 mg/day and 300 mg/day respectively one year, was not being followed-up regularly. The patient had complaints such as suicidal thoughts and insomnia since the onset and gained 10 kg during the treatment. She was using ramipril 5 mg/day and her blood pressure follow-ups were normal. The venlafaxine dose of the patient was elevated to 150 mg/day and dose of quetiapine was remained same at 300 mg/day. Aripiprazol with a dose of 5 mg/day was added to the treatment of the patient due to complaints on the follow-up after a month. On the next one month follow up after the aripiprazole administration, patient stated that she suffered from insomnia, restlessness on legs, urge to move her legs and she had ceased the medication after 5 days. Her complaints were recovered after the cessation of the aripiprazole administration. The biochemistry, blood glucose, hemogram, iron, ferritine, transferrin level, renal hepatic test results, thyroid function tests, B12, and folic acid levels of the patient were all within normal range. Patient was evaluated by the departments of neurology and internal medicine and no peripheral neuropathic or vascular disease were found. There were no similar complaints before the aripiprazole treatment. Treatments of venlafaxine 150 mg/day and quetiapine 300 mg/day were continued. Venlafaxine dose was elevated to 225 mg/day but this dose was terminated gradually due to onset hypertension and depressive findings, duloxetine treatment with a dose of 30 mg/day was initiated, treatment of quetiapine 300 mg/day was resumed as unchanged. Duloxetine dose was increased up to 120 mg/day. RLS symptoms were not recurred during this period. Depressive symptoms of the patient remitted and treatment have been proceeding for one year. In our case, the symptoms have been considered as a result of aripiprazole administration due to occurrence of the symptoms after the initiation of aripiprazole treatment, recovery of the symptoms after cessation of aripiprazole, absence of and organic disease causing RLS, normal lab results, and lack of similar picture in patient’s history. The patient has been using venlafaxine and quetiapine for one year and no RLS symptoms were reported since then. Although the onset venlafaxine and quetiapine medication was proceeding, RLS symptoms were not observed after cessation of aripiprazole. In literature, a case of RLS related with the combination of venlafaxine and quetiapine was reported. RLS symptoms were remitted when aripiprazole was added to treatment. The inflammation of the RLS by D2 receptor antagonists and well response of the symptoms to dopaminergic drugs such as levodopa, suggest that the dopaminerg","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86375583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-12-01DOI: 10.5455/BCP.20160224101558
M. Yuruyen, H. Yavuzer, Filiz Demirdağ, Zehra Kara, M. Cengiz, S. Yavuzer, A. Doventas, D. Erdinçler, T. Beǧer
Objective: Polypharmacy, quite common in elderly patients, is an important issue, resulting in increased morbidity and mortality. This study aimed to examine polypharmacy rates and drug usage chara...
{"title":"Is Depression a Predictive Factor for Polypharmacy in Elderly","authors":"M. Yuruyen, H. Yavuzer, Filiz Demirdağ, Zehra Kara, M. Cengiz, S. Yavuzer, A. Doventas, D. Erdinçler, T. Beǧer","doi":"10.5455/BCP.20160224101558","DOIUrl":"https://doi.org/10.5455/BCP.20160224101558","url":null,"abstract":"Objective: Polypharmacy, quite common in elderly patients, is an important issue, resulting in increased morbidity and mortality. This study aimed to examine polypharmacy rates and drug usage chara...","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76167276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：